← Volver a la portada
Asia · Mercados regionales · Vietnam Investment Review

Yicura BioMed completes first closing of Series B financing

Publicado por Vietnam Investment Review · Vietnam hace 16 h
Yicura BioMed completes first closing of Series B financing
Yicura BioMed completes first closing of Series B financing · Vietnam Investment Review

Resumen detallado

Clinical-stage immunotherapy firm Yicura BioMed completed the first closing of its Series B funding round led by Gobi Partners on 13 November 2026 to advance its ICVAX HIV product.

HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("Yicura"), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing medicines for infectious diseases, cancers, and inflammatory diseases, is pleased to announce today the first closing of its Series B financing led by Gobi Partners, with participation from a number of strategic investors from Wuxi and institutional investors from Hong Kong. Their participation reflects shared confidence in Yicura's clinical development path.

The issuer is solely responsible for the content of this announcement.

Inicio del artículo, extracto de Vietnam Investment Review. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Vietnam Investment Review Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (vir.com.vn)

También te puede interesar